

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 6-K**

---

**REPORT OF FOREIGN ISSUER  
PURSUANT TO RULE 13a-16 OR 15d-16  
OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of July 2020**

**(Commission File No. 001-39308)**

---

**CALLIDITAS THERAPEUTICS AB**

**(Translation of registrant's name into English)**

---

**Kungsbron 1, C8  
SE-111 22**

**Stockholm, Sweden**

**(Address of registrant's principal executive office)**

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

---

---

Enclosed hereto is a copy of an announcement published by Calliditas Therapeutics AB on July 24, 2020.

The information contained in this Form 6-K, including Exhibit 99.1, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

**EXHIBIT INDEX**

<b>Exhibit</b>	<b>Description</b>
99.1	Company announcement dated July 24, 2020

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**CALLIDITAS THERAPEUTICS AB**

Date: July 27, 2020

By: /s/ Fredrik Johansson  
Fredrik Johansson  
Chief Financial Officer

---



Stockholm, Sweden

July 24, 2020

## **Calliditas reorganizes its management team**

**Calliditas Therapeutics AB (publ) (“Calliditas”) today announced that it has reorganized its management team.**

From today, the company’s management team will consist of:

Renée Aguiar-Lucander, CEO  
Fredrik Johansson, CFO  
Dr Richard Philipson, CMO  
Frank Bringstrup, Vice President Regulatory Affairs  
Andrew Udell, Head of North America, Commercial  
Katayoun Welin-Berger, Vice President Operations

“Calliditas will continue to build and benefit from a broad and highly competent senior team which operates in an integrated manner. As the company has grown there is now need for a smaller and more focused executive group to support this structure and continue to leverage this cross functional expertise.”, said CEO Renée Aguiar-Lucander.

Due to the growing number of employees in the US, Andrew Udell has been appointed as Head of North America, Commercial and will be responsible for implementation and execution of medical affairs, market access, as well as sales and marketing in the US.

**For further information, please contact:**

Renée Aguiar-Lucander, CEO at Calliditas  
Tel.: +46 722 52 10 06, email: [renee.lucander@calliditas.com](mailto:renee.lucander@calliditas.com)

Mikael Widell, Head of Communications and IR  
Tel.: +46 703 11 99 60, email: [mikael.widell@calliditas.com](mailto:mikael.widell@calliditas.com)

*The information was sent for publication, through the agency of the contact persons set out above, on July 24, 2020 at 8:00 a.m. CET.*

### **About Calliditas**

Calliditas Therapeutics is a specialty pharmaceutical company based in Stockholm, Sweden focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs. Calliditas' lead product candidate, Nefecon, is a proprietary, novel oral formulation of budesonide, an established, highly potent local immunosuppressant, for the treatment of the autoimmune renal disease IgA nephropathy, or IgAN, for which there is a high unmet medical need and there are no approved treatments. Calliditas is running a global Phase 3 study within IgAN and, if approved, aims to commercialize Nefecon in the United States. Calliditas is listed on Nasdaq Stockholm (ticker: CALTX) and the Nasdaq Global Select Market (ticker: CALT). Visit [www.calliditas.com](http://www.calliditas.com) for further information.

---